Belite Bio, Inc (BLTE)
Nasdaq: BLTE · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2021
Who owns Belite Bio, Inc
As filed with the SECHolders of 5% or more
2
Lin Bioscience International Ltd. holds 53.7% of Ordinary shares, par value US$0.0001 per share, as its SCHEDULE 13G filed Jan 21, 2025 says.
Directors and officers
9
report now, of 9 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Lin Bioscience International Ltd.
SCHEDULE 13G · filed Jan 21, 2025 · Ordinary shares, par value US$0.0001 per share
Darwin Global Management, Ltd.
SCHEDULE 13G/A · filed Feb 17, 2026 · Ordinary Shares, par value US$0.0001 per share · 7% in Dec 10, 2025
Yu-Hsin Lin
SCHEDULE 13G/A · filed May 14, 2026 · Ordinary shares, par value US$0.0001 per share · reported falling below 5%, from 7.1% in Jan 21, 2025
What BLTE reports owning in othersstakes of 5% or more, and other ties
8 subsidiaries in 7 countries, from the list filed with the 20-F filed Mar 31, 2026.
Insider tradesForm 4
175sales
0purchases
162sales on a scheduled plan
5people selling
$40.6Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 30, 2025 to Oct 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 9 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Lin Yu-Hsin | Chief Executive Officer | 25 | $20.8M | 25 | 0 | $0 |
| Chuang Hao-Yuan | Chief Financial Officer | 25 | $14.0M | 25 | 0 | $0 |
| Scholl Hendrik Peter | Chief Medical Officer | 21 | $2.9M | 8 | 0 | $0 |
| Mata Nathan L. | Chief Scientific Officer | 103 | $2.7M | 103 | 0 | $0 |
| Chen Wan-Shan | director | 1 | $200,000 | 1 | 0 | $0 |